According to the receptor status of the breast tumor, the axillary pCR rate was 13% (34/260) for ER+/HER2− tumors, 56% (86/153) for ER−/HER2− tumors, 82% (106/130) for ER−/HER2+ tumors, and 58% (107/184) for ER+/HER2+ tumors. This evidence concerns the gene ERBB2 and breast neoplasm.